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Abstract 
Nutrient sulfate is essential for numerous physiological functions in mammalian growth 
and development. Accordingly, disruptions to any of the molecular processes that maintain 
the required biological ratio of sulfonated and unconjugated substrates are likely to have 
detrimental consequences for mammalian physiology. Molecular processes of sulfate 
biology can be broadly grouped into four categories: firstly, intracellular sulfate levels are 
maintained by intermediary metabolism and sulfate transporters that mediate the transfer 
of sulfate across the plasma membrane; secondly, sulfate is converted to 3’-
phosphoadenosine 5’-phosphosulfate (PAPS), which is the universal sulfonate donor for all 
sulfonation reactions; thirdly, sulfotransferases mediate the intracellular sulfonation of 
endogenous and exogenous substrates; fourthly, sulfate is removed from substrates via 
sulfatases. From the literature, we curated 91 human genes that encode all known sulfate 
transporters, enzymes in pathways of sulfate generation, PAPS synthetases and 
transporters, sulfotransferases and sulfatases, with a focus on genes that are linked to 
human and animal pathophysiology. The predominant clinical features linked to these 
genes include neurological dysfunction, skeletal dysplasias, reduced fecundity and 
reproduction, and cardiovascular pathologies. Collectively, this review provides reference 
information for genetic investigations of perturbed mammalian sulfate biology. 
 
Key Words 
Sulfate; Pathogenetics; Transport; Sulfotransferase; Sulfatase; PAPS 
  
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
Page 3 of 41 
 
1. Introduction 
Sulfate plays an important role in numerous biochemical and cellular processes in 
mammalian physiology (Fig. 1A) (Dawson, 2011).  In most cases, sulfonation leads to the 
inactivation of steroids, thyroid hormone and neurotransmitters, as well as Phase II 
metabolism and detoxification of xenobiotics and certain drugs such as paracetamol 
(Mulder and Jakoby, 1990; Darras et al., 1999; Richard et al., 2001; Yamaguchi, 2001; 
Stanley et al., 2005; Alnouti, 2009; Dawson, 2012). Sulfonation of glycosaminoglycans is 
also required to maintain the structure and function of tissues (Habuchi et al., 2004; 
Klüppel, 2010). Despite the essential roles for sulfate in maintaining healthy growth and 
development, the physiological importance of sulfate is often underappreciated in clinical 
settings. 
In children and adults, the diet provides approximately one third of daily requirements 
(Allen et al., 1989; Florin et al., 1991; Florin et al., 1993). Certain foods including brassica 
vegetables and commercial breads, as well as mineral waters, contain abundant levels of 
sulfate which is absorbed into circulation via active transport in the small intestine 
(Dawson, 2011). Circulating levels are then maintained at approximately 0.3 mmol/L by the 
kidneys, which filter sulfate in the glomerulus and then reabsorb sulfate in the proximal 
tubule (Murer et al., 1992; Cole and Evrovski, 1997). The first step of reabsorption is 
mediated by the solute linked carrier 13A1 (SLC13A1) sulfate transporter on the apical 
membrane of renal epithelial cells, and the second step via the SLC26A1 sulfate-anion 
exchanger on the basolateral membrane (Lotscher et al., 1996; Karniski et al., 1998). 
Circulating sulfate is then taken up by cells throughout the body via tissue specific sulfate 
transporters. 
In addition to sulfate provided from circulation, the intracellular needs for sulfate are also 
supplied via intermediary metabolism of sulfur-containing amino acids, methionine and 
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cysteine (Mulder, 1981; Turner et al., 2006). Methionine is metabolized to cysteine via the 
transsulfuration pathway (Dawson et al., 1996), and cysteine is then oxidized to sulfate via 
two pathways, including a major pathway involving cysteine dioxygenase (Ueki et al., 2011)  
(Fig. 1B). Sulfur-containing gases, including hydrogen sulfide and sulfur dioxide, can also be 
oxidized to generate sulfate (Mitsuhashi et al., 2005; Olson, 2015). The removal of sulfate 
from substrates via sulfatases, particularly in the lysozyme, also contributes to the flux of 
sulfate availability within cells (Dawson et al., 2015a). Together, a sufficient supply of 
sulfate from circulation and the above mentioned intracellular pathways are required for 
sulfonation reactions to function effectively. 
Sulfate is converted into 3’-phosphoadenosine 5’-phosphosulfate (PAPS), which is the 
universal sulfonate (SO32-) donor for all sulfonation reactions (Fig. 1B) (Klassen and Boles, 
1997). In both humans and animals, PAPS synthesis is mediated by PAPS synthetase in two 
steps: firstly the sulfurylation of ATP to form adenosine 5’-phosphosulfate (APS), followed 
by phosphorylation to form PAPS (Venkatachalam, 2003). Sulfotransferases (SULT) in the 
cytoplasm mediate the sulfonation of steroids, thyroid hormone, xenobiotics, 
neurotransmitters and bile acids, whereas Golgi-membrane bound sulfotransferases (ST) 
mediate the sulfonation of proteoglycans and lipids (Fig. 1B) (Gamage et al., 2006).  ST-
mediated sulfonation is reliant on the transport of PAPS into the Golgi via the SLC25B2 and 
SLC35B3 PAPS transporters that are expressed on the Golgi membrane (Sasaki et al., 2009). 
The required biological ratio of sulfonated to unconjugated substrates is also maintained by 
the removal of sulfate via sulfatases (Hanson et al., 2004). 
 
In recent years, animal models of perturbed sulfate biology have demonstrated the 
essential roles of numerous genes involved in sulfate biology, leading to increased clinical 
interest in this field (Dawson, 2011, 2013; Dawson et al., 2015a). This review highlights our 
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current knowledge of the 91 genes that contribute to maintaining sulfate homeostasis, with 
a particular emphasis on the pathogenetics of sulfate biology in humans and animal models. 
 
2. Genes involved in maintaining sulfate homeostasis 
Over the past decade, numerous studies have focused on individual genes or gene families, 
and these have been previously summarized elsewhere, including reviews on sulfate 
transporters (Dawson and Markovich, 2005, 2007), PAPS synthesis and transport 
(Venkatachalam, 2003; Nishihara, 2014), sulfate generation from amino acids (Mulder, 
1981), sulfotransferases (Gamage et al., 2006) and sulfatases (Hanson et al., 2004). This 
review brings together all of the genes from each functional group, including current 
nomenclature and all known alias names reported to date (Tables 1‒4). In addition, we 
summarize the chromosomal locations of all listed genes, which show the significance of 
most autosomes and the X-chromosome in maintaining sulfate homeostasis. 
Approximately half of the genes (n = 47/91) are found on six chromosomes (2, 4, 5, 7, 16 
and X), whereas none are located on chromosomes 9, 7 and 14 (Fig. 2). Some related genes 
are located within the same chromosome arm, suggesting a gene duplication event during 
evolution, including: SLC13A1 and SLC13A4 at 7q31-33; SLC35B2 and SLC35B3 at 6p21-24; 
SULT1A1, SULT1A2 and SULT1A3 at 16p11-12; SULT1C2, SULT1C3 and SULT1C4 at 2q12; 
SULT2A1 and SULT2B1 at 19q13; CHST4, CHST5 and CHST6 at 16q22; STS, ARSD, ARSE, 
ARSF and ARSH at Xp22.3. These gene clusters are relevant when considering that deletions 
at these chromosomal locations have been associated with neurological disorders (Lin et 
al., 2009; Ben Khelifa et al., 2013; Pinto et al., 2014; Rai and Sharif, 2015; Rudd et al., 2015; 
Urquhart et al., 2015; Fedorenko et al., 2016; Scheps et al., 2016), which is one of the most 
consistent clinical features of disturbed sulfate biology (Fig. 3) and highlights the important 
roles of sulfate in brain physiology. 
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2.1 Sulfate transporter genes 
The human genome contains 11 sulfate transporter genes belonging to the solute linked 
carrier 4 (SLC4), SLC13 and SLC26 gene families. SLC4A1 is an anion exchanger, with 
chloride and bicarbonate being the predominant substrates, but can also cotransport 
sulfate and H+ in exchange for chloride (Jennings, 1976). The contribution of SLC4A1 in 
maintaining sulfate homeostasis in mammalian physiology is unclear and the major 
phenotypes linked to mutations in SLC4A1, including hereditary spherocytosis in red blood 
cells and distal renal tubular acidosis in the kidney, have been attributed to perturbed 
chloride and bicarbonate exchange (Bruce et al., 1997; Bruce et al., 2005). 
SLC13A1 and SLC13A4 are Na+-dependent sulfate transporters that are primarily expressed 
in the kidney and placenta, respectively (Lotscher et al., 1996; Simmons et al., 2013). 
Disruption of the SLC13A1 gene leads to renal sulfate wasting and hyposulfataemia in 
humans, mice, dogs and sheep (Dawson et al., 2003; Bowling et al., 2012; Neff et al., 2012; 
Zhao et al., 2012), whereas loss of the SLC13A4 gene blocks placental sulfate supply to the 
developing fetus, which causes severe developmental abnormalities and late gestational 
fetal death in mice (Rakoczy et al., 2015b). Interestingly, disruptions to the SLC13A1 and 
SLC13A4 genes do not cause any major cellular pathology in the tissues where these genes 
are expressed but rather lead to reduced circulating sulfate levels which in turn decreases 
sulfonation capacity in cells throughout the body (Dawson et al., 2003; Lee et al., 2006; 
Rakoczy et al., 2015b). In particular, certain cells such as chondrocytes, endothelial cells 
and hepatocytes, which have a high sulfate requirement, are linked to skeletal, vascular and 
hepatic metabolism phenotypes in animals with disrupted SLC13A1 and SLC13A4 genes 
(Table 5). 
Eight members of the SLC26 gene family exchange sulfate for other anions including 
chloride, bicarbonate and oxalate (Dawson and Markovich, 2005). To date, five members of 
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the SLC26 family have been linked to human pathologies: SLC26A2 is linked to four types of 
chondrodysplasias; SLC26A3 is defective in congenital chloride diarrhea and metabolic 
acidosis; SLC26A6 mutations are associated with kidney stones; SLC26A8 is associated with 
spermatogenic failure; SLC26A9 is linked to idiopathic bronchiectasis (Table 5). In addition, 
Slc26a1 has been linked to renal stones and paracetamol-enhanced liver toxicity in mice 
(Dawson et al., 2010b), which may be relevant to genetic variants in the SLC26A1 genes of 
certain patients with calcium oxalate urolithiasis (Dawson et al., 2013). Whilst the SLC26 
gene family shares significant structural and sequence similarity, the phenotypes linked to 
each gene are quite distinct which is likely due to the different tissue distribution of each 
transporter as well as the various anions that are exchanged with sulfate (Dawson and 
Markovich, 2005). 
 
2.2 Sulfate generation genes 
Adults and children have the capacity to metabolise the sulfur-containing amino acids 
methionine and cysteine to sulfate (Fig. 1B) (Dawson et al., 2015a). The transsulfuration 
pathway converts methionine to cysteine (Dudman et al., 1996), which is then catabolized 
to sulfate via two pathways (Ueki et al., 2011): a major pathway that relies on cysteine 
dioxygenase (CDO1) and glutamic-oxaloacetic transaminase 1 (GOT1), and a minor 
pathway involving cystathionine β-synthase (CBS), γ-cystathionase (CTH), sulfide quinone 
reductase (SQRDL) and thiosulfate sulfurtransferase (TST). The latter pathway generates 
hydrogen sulfide from cysteine via CBS, either in the cytosol or mitochondria, which is then 
oxidized via SQRDL and TST in the mitochondria (Olson, 2015). Hydrogen sulfide can also 
be converted to sulfur dioxide, via nicotinamide-adenine dinucleotide phosphate oxidase 
(Mitsuhashi et al., 2005), which is further converted to sulfite and sulfate (Fig. 1B). The final 
step of both pathways requires sulfite oxidase (SUOX) to generate sulfate. The negligible 
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CDO1 and CTH gene expression in human and rodent fetal tissues (Gaull et al., 1972; 
Loriette and Chatagner, 1978; Rakoczy et al., 2015a), suggests that the developing fetus 
lacks the capacity to generate sulfate and likely explains the late gestational fetal death in 
Slc13a4 null-mice when placental sulfate supply from mother to fetus is blocked (Rakoczy 
et al., 2015b). 
Whilst previous studies have attributed the pathogenetics of the above genes to excess 
levels of pathway intermediates (e.g., hyperhomocysteinemia with CBS; sulfite and 
sulfocysteine with SUOX) (Dawson et al., 1996; Bosley et al., 2014), the contribution of 
intracellular sulfate deficiency from blocks in these pathways has not been considered. This 
is relevant when considering that these pathways contribute approximately 2/3 of 
intracellular sulfate requirements (Dawson et al., 2015a). Accordingly, the contribution of 
genetic defects in the CDO1, GOT1, CBS, CTH, SQRDL, TST and SUOX genes to altered sulfate 
homeostasis awaits further investigation. 
 
2.3 PAPS synthetase and transporter genes 
All sulfonation reactions in animals require the conversion of sulfate to the universal 
sulfonate (SO3-) donor, PAPS (Klassen and Boles, 1997). PAPS is generated via PAPS 
synthetase in the cytosol, by sulfurylation of ATP to form APS followed by phosphorylation 
to form PAPS (Fig. 1B) (Venkatachalam, 2003). Mutations in the PAPSS2 gene have been 
linked to developmental dwarfism disorders, including spondyloepimetaphyseal dysplasia 
in humans, and brachymorphism in mice (Table 5). However, disruption of the PAPSS1 gene 
has not been reported in any human pathology but is proposed to be embryologically lethal 
due to its abundant expression in the developing nervous system and bone marrow (Strott, 
2002). 
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The sulfonate group from PAPS is transferred to the target substrate in either the cytosol or 
the Golgi, with the latter requiring PAPS transporters (SLC35B2 and SLC35B3) to mediate 
the translocation of PAPS from the cytosol into the Golgi (Sasaki et al., 2009). Cartilage 
defects and lethal phenotypes have been linked to Slc35b2 in Zebrafish and Drosophila 
(Kamiyama et al., 2003; Clément et al., 2008), whereas up-regulation of SLC35B2 mRNA 
expression is associated with poor prognosis of invasive ductal breast carcinoma in humans 
(Chim-ong et al., 2014). 
The landmark paper reporting sulfate activation to PAPS (Lipmann, 1958) and the 
following identification of sulfotransferases (Lipmann, 1958; Gamage et al., 2006), as well 
as the characterisation of animal models of perturbed sulfate homeostasis (Tables 5‒7), 
have led to our current understanding of sulfate biology genetics, and the physiological 
importance of sulfate in modulating the biological activity of neurotransmitters (Coughtrie 
et al., 1998; Lee et al., 2007), steroids (Dawson, 2012), thyroid hormone (Richard et al., 
2001; Wu et al., 2005), proteoglycans and xenobiotics (Habuchi et al., 2004; Klüppel, 2010). 
 
2.4 Sulfotransferase genes 
Sulfotransferases, can be grouped into two classes: (i) SULTs which sulfonate 
neurotransmitters, bile acids, xenobiotics and steroids; (ii) Golgi-located STs that have 
proteoglycan and lipid substrates (Gamage et al., 2006). The overlapping substrate 
specificity and tissue expression of the SULTs suggest they are not individually critical, and 
most likely explain why pathogenetic defects in this family of cytosolic sulfotransferases 
have not been reported for humans. However, disruption of the estrogen sulfotransferase 
gene Sult1e1 led to mid-gestational fetal loss and placental thrombosis in mice (Tong et al., 
2005), indicating that complete loss of certain SULTs can be embryonic lethal but this has 
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yet to be determined for humans. The potential role of steroid sulfotransferases SULT1E1 
and SULT2A1 in the induction and maintenance of hormone-dependent cancers has been 
reported. Reduced expression of SULT2A1 is found in hepatocellular carcinoma cells 
(Huang et al., 2005), whereas SULT1E1 activity is less abundant in breast cancer cell lines 
when compared to normal breast cell lines (Falany et al., 2002; Tanaka et al., 2003). 
SULT2A1 genetic variants have also been associated with a lower ratio of DHEA-sulfate to 
DHEA in children with premature adrenarche, as well as adrenal androgen excess in some 
women with polycystic ovary syndrome (Goodarzi et al., 2007; Utriainen et al., 2012). 
Further studies are required to determine the role of SULTs in certain cancers and altered 
endocrine profiles. 
To date, 37 human Golgi membrane bound STs have been reported, with seven of these 
genes (CHST3, CHST6, CHST8, CHST14, HS6ST1, GAL3ST4 and NDST1) linked to human 
pathologies (Table 6). These STs mediate the sulfonation of proteoglycans, including 
chondroitin sulfate, heparan sulfate and keratin sulfate, which are essential for maintaining 
the structure and function of connective tissues in the body, particularly in the eye, skin and 
developing skeleton (Habuchi et al., 2004; Klüppel, 2010). Sulfonated proteoglycans are 
also a component of the mucous barrier which protects the epithelial layer of the gut, lungs 
and reproductive tract (Nieuw Amerongen et al., 1998; Argüeso and Gipson, 2006; Dawson 
et al., 2009). Accordingly, the phenotypes associated with disrupted ST genes in humans 
and mice include conditions affecting the structural integrity of the eye, skin, joints and 
lungs, as well as reduced fecundity (Table 6). 
 
2.5 Sulfatase genes 
The human genome contains 17 sulfatase genes and one sulfatase modifying factor gene, 
SUMF1, which is critical for post-translational modification of all sulfatases (Table 4) 
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(Cosma et al., 2003; Sardiello et al., 2005). Within the lysosome (Fig. 1B), defective removal 
of sulfate from sulfoglycolipids (via ARSA) and proteoglycans (via ARSB, GALNS, GNS, IDS 
and SGSH) leads to lysosomal storage disorders, that have progressive clinical features with 
late infantile, juvenile or adult onset (Diez-Roux and Ballabio, 2005; Ashworth et al., 2006; 
Eckhardt, 2008). Steroid sulfatase (STS) deficiency leads to X-linked ichthyosis which 
presents after birth (Honour et al., 1985), whereas ARSE is linked to X-linked 
chondrodysplasia punctata that manifests in the prenatal period (Horikoshi et al., 2010). 
The SULF1 and SULF2 sulfatases are secreted to the cell surface in numerous fetal tissues, 
including bone and cartilage, where they mediate the removal of 6-O-sulfate from heparan 
sulfate, which enhances growth factor signaling during development (Ratzka et al., 2010). 
The human SULF1 gene has been linked to mesomelia-synostoses syndrome that has 
clinical features of limb shortening and acral synostoses (Isidor et al., 2010). Similar 
developmental defects are observed in Sulf1 and Sulf2 null mice (Holst et al., 2007). The 
severe and lethal developmental defects linked to the human and rodent SUMF1 gene, 
which causes multiple sulfatase deficiency, highlight the essential roles of sulfatases in 
maintaining healthy growth and development. 
 
3. Phenotypes of disturbed sulfate biology 
In humans, 28 of the listed 91 genes have been linked to pathophysiology (Tables 5‒7). This 
finding suggests that many of the genes reported in this review, may have some 
redundancy, particularly the sulfotransferases which have overlapping substrate 
specificities and are expressed in multiple tissues (Gamage et al., 2006). However, of the 63 
genes in our list which are not reported in human pathologies, there are 15 genes that are 
linked to pathologies in animals with most being embryonic lethal. This is relevant to the 
important roles of sulfate in fetal development and suggests that our list most likely 
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contains genes yet to be associated with human fetal loss. Importantly, the clinical features 
linked with the human genes in our list (Tables 5‒7) give similar phenotypes in animal 
models, further supporting their conserved physiological roles across species. Overall, from 
the 43 genes in our list that are linked to pathophysiology in humans and animals, almost 
half of those genes are linked to neurological dysfunction (n = 16), perturbed skeletal 
growth and development (n = 19), or perturbed reproduction and fecundity (n = 16) in 
humans and/or animals. These features correlate to the relatively high abundance of those 
genes in brain, skeletal and reproductive tissues (Fig. 3), as well as the essential 
requirement for sulfate in the developing fetus (Dawson, 2011). In addition, cardiovascular 
phenotypes are associated with nine genes reported in this review (Fig. 3). Whilst there are 
numerous pathological features associated with the 43 genes, the following sections focus 
on predominant features, including neurological dysfunction, skeletal dysplasias, reduced 
fecundity and reproduction, and cardiovascular pathologies. The potential involvement of 
several sulfate maintenance genes in cancer has also gained attention from the scientific 
community in recent years, and those findings have been reviewed elsewhere (Dawson et 
al., 2010a; Dawson, 2012; Daniels and Kadlubar, 2013; Rižner, 2016). 
 
3.1 Neurological dysfunction linked to sulfate maintenance genes 
Disturbances of sulfate metabolism have been linked with several disorders that have 
neurological dysfunction as a major clinical feature, including ARSA with metachromatic 
leukodystrophy, ARSB with Maroteaux–Lamy syndrome, IDS with Hunter’s syndrome, SGSH 
with Sanfilippo A syndrome, NDST1 with intellectual disability, and SUMF1 with multiple-
sulfohydrolase deficiency (Tables 6‒7). All of these genes are expressed in the brain as well 
as multiple other tissues (Fig. 3), which likely explains the additional clinical features 
associated with these disorders. Disruption of these genes in animals also leads to brain 
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dysfunction phenotypes that closely model the human situation, such as ARSB in mouse, rat, 
cat and dog (Table 7). In addition, neurological features are observed with mouse Slc13a1 
(seizures and behavioural abnormalities) and Sulf2 (hippocampal and cerebellar neuron 
deficits, and behavioural abnormalities), as well as Arsg in dog (cerebellar ataxia) and 
mouse (neuronal cell death and behavioural deficits). These findings are relevant to the 
numerous roles of sulfate in the brain including sulfonation of neurotransmitters, thyroid 
hormone, neurosteroids, lipids and proteoglycans. 
Sulfate is a major component of proteoglycans and cerebroside sulfate, which contributes to 
maintaining the structure and function of neural tissues (Mulder and Jakoby, 1990), 
particularly during fetal neurodevelopment (Dawson, 2013). Importantly, the sulfate 
content of glycoproteins, such as heparan sulfate and chondroitin sulfate, plays an 
important role in neurogenesis, including the modulation of axonal guidance, neuronal 
outgrowth, and synapse development (Yamaguchi, 2001; Schwartz and Domowicz, 2004; 
Carulli et al., 2005). In addition, sulfonation modulates the actions of neurosteroids on 
glutamatergic, GABAA, N-methyl-D-aspartate and sigma-opioid receptors (Kríz et al., 2008). 
For example, pregnenolone is a barbiturate-like agonist, whereas pregnenolone-sulfate is a 
picrotoxin-like agonist. Other examples include sulfonated DHEA which stimulates 
acetylcholine release from the hippocampus, whereas unconjugated DHEA does not (Kríz et 
al., 2008). This latter finding is relevant when considering the decreased DHEA-sulfate to 
DHEA ratio in the hyposulfataemic Slc13a1 null mouse which also exhibits behavioural 
abnormalities (Dawson et al., 2004, 2005, 2008). 
Studies in sheep showed that radio-tracer [35S]-sulfate administration to pregnant ewes led 
to the high abundance of [35S]-sulfate in the fetal brain, with levels peaking in the third 
trimester (Hansard and Mohammed, 1968), demonstrating the incorporation of maternally-
derived sulfate into the developing fetal brain. Sulfonated substrates are also actively 
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
Page 14 of 41 
 
supplied to the developing brain. For example, iodothyronines are sulfonated in the 
placenta via the SULT1A1 sulfotransferase, and then transported into fetal circulation 
where they are taken up by fetal tissues, including the brain (Richard et al., 2001). Local 
concentrations of sulfonated (active) and unconjugated (inactive) T3 within the brain are 
regulated via the actions of ARSC sulfatase and SULT1A1 sulfotransferase, which provides a 
means of protecting the fetus from excessive unconjugated active T3 (Richard et al., 2001). 
 
 
3.2 Skeletal dysplasias linked to sulfate maintenance genes  
Skeletal defects are one of the most widely investigated clinical features linked to perturbed 
sulfate biology (Dawson and Markovich, 2005, 2007). The genetic basis of sulfate biology in 
the skeletal sulfation disorders is well researched and has been linked to defects in the 
sulfate transporter SLC26A2, synthetase PAPSS2, sulfotransferases (CHST3 and CHST14) 
and several sulfatases (IDS, GNS, SGSH, NDST1, ARSA, SULF1, ARSB, ARSE and STS) (Tables 5-
7).  
More than two decades ago, the sulfate transporter gene SLC26A2 was linked to diastrophic 
dysplasia (DTD), which is a moderately severe chondrodysplasia that typically presents 
with short-limbed dwarfism and generalized dysplasias of the joints (Hastbacka et al., 
1994). To date, over 30 mutations in the human SLC26A2 gene have been linked to 
chondrodysplasias (Dawson and Markovich, 2005), with the underlying metabolic defect 
being reduced sulfate content of chondroitin in chondrocytes (Cornaglia et al., 2009). The 
extent of impaired chondroitin sulfonation correlates to clinical severity, with mutations in 
SLC26A2 leading to four different chondrodysplasias, ranging from mild to lethal: Multiple 
epiphyseal dysplasia (MED), DTD, atelosteogenesis Type II (AO2), and achondrogenesis 
Type IB (ACG1B). The correlation between sulfonation capacity and clinical severity 
suggests that therapeutic approaches which are aimed at increasing sulfonation capacity in 
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the skeleton could potentially ameliorate the skeletal pathology linked to SLC26A2. This 
approach is relevant when considering the chondrodysplasia phenotype of the mutant 
Slc26a2 mouse can be improved by administration of thiol-containing compounds, such as 
dietary N-acetyl cysteine that can bolster sulfate supply (Forlino et al., 2005; Pecora et al., 
2006; Cornaglia et al., 2009). 
In recent years, the skeletal phenotypes linked to SLC26A2 and PAPPS2 in humans and 
animals have expanded to include knee osteoarthritis (Ikeda et al., 2001). In addition, the 
SLC13A1 sulfate transporter which maintains circulating sulfate level, has been associated 
with osteochondrodysplasias in sheep and dogs (Neff et al., 2012; Zhao et al., 2012), 
suggesting that perturbed sulfate biology is likely to be more prevalent than the estimated 
2% of all human skeletal dysplasias which is based on live births (Stevenson et al., 2012).  
 
3.3 Reduced reproduction and fecundity linked to sulfate maintenance genes 
Interest in sulfate biology during human gestation has expanded following the 
characterisation of fetal demise in animal models of reduced sulfonation capacity (Tables 
5‒7). For example, disruption of the sulfate transporter gene Slc13a1 in pregnant female 
mice leads to maternal and fetal hyposulfataemia, as well as late gestational fetal loss 
(Dawson et al., 2003, 2011). A related sulfate transporter in the placenta, Slc13a4, which 
mediates sulfate supply from mother to fetus during pregnancy (Dawson et al., 2012; 
Simmons et al., 2013), has also been linked to severe fetal developmental defects and death. 
These animal studies highlight the importance of maintaining high maternal sulfate levels 
in pregnancy, as well as supplying sulfate to the fetus via placental sulfate transporters. 
In pregnant women, plasma sulfate levels increase by approximately 2-fold in early 
pregnancy (10‒20 weeks gestation), with levels peaking in late gestation (30‒37 weeks) at 
a time when fetal demands for sulfate are high (Dawson et al., 2015b). Similarly, circulating 
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sulfate levels are increased in mouse gestation, which is mediated by increased expression 
of the renal Slc13a1 and Slc261 sulfate transporter genes that enhance sulfate reabsorption 
from the urinary filtrate back into circulation (Dawson et al., 2012). Further research into 
the potential pathogenetic roles of the SLC13A1, SLC26A1 and SLC13A4 genes in human 
pregnancy is warranted based on animal studies, as well as known genetic variants in these 
human genes (Dawson and Markovich, 2005, 2007; Dawson et al., 2013), particularly those 
loss-of-function variants leading to hyposulfataemia (Lee et al., 2006; Bowling et al., 2012). 
 
Steroid sulfonation also contributes to maintaining pregnancy and healthy fetal growth and 
development. Sulfonated steroids are the major form of steroids supplied to fetal tissues. 
For example, estradiol is sulfonated in the placenta (E2-3-S) and then taken up by the fetal 
brain where it is de-sulfonated by STS sulfatase to E2, which is a potent stimulator of fetal 
adrenocorticotropin (ACTH) secretion and the hypothalamus-pituitary-adrenal (HPA) axis 
(Wood, 2005). These findings are relevant to the role of the SULT1E1 estrogen 
sulfotransferase which is abundantly expressed in the placenta where it mediates 
sulfonation of E2, as well as estrone (E1) and estriol (E3) (Dawson, 2012). Disruption of the 
Sult1e1 gene in pregnant female mice leads to placental thrombosis and mid-gestational 
fetal loss (Tong et al., 2005). Sult1e1 is also expressed in the testis, where its disruption 
leads to reduced sperm motility, seminiferous tubule damage, Leydig cell 
hypertrophy/hyperplasia, and reduced fecundity of male mice. Spermatogenic failure is 
also linked to a mutation found in the human SLC26A8 anion sulfate transporter (Dirami et 
al., 2013), which is most abundantly expressed in the testis (Fig. 3). Similar phenotypes are 
observed in the male Slc26a8 null mouse, with the proposed molecular dysfunction being 
attributed to perturbed chloride and bicarbonate fluxes during sperm capacitation (Rode et 
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al., 2012a). Accordingly, the contribution of altered sulfate homeostasis to disrupted 
SLC26A8 function requires further investigation. 
Endocrine disruption has also been linked to Chst8 in mice, which exhibits increased sex 
hormones, testosterone and luteinizing hormone (LH) (Mi et al., 2008b). These hormonal 
disturbances cause precocious sexual maturation and an increase in litter numbers and 
fecundity. Chst8 is highly expressed in the pituitary gland and the disturbance of this 
sulfotransferase leads to increased levels of non-sulfonated LH (the active form of LH), 
which up-regulates the hypothalamic-pituitary-gonad axis via increased testosterone and 
estrogen levels in male and female mice, respectively (Mi et al., 2008a).  
Sulfate also contributes an important role in fertilization, particularly during oocyte 
maturation when sulfonated zona pellicida glycoproteins contribute to the process of 
accepting sperm (Lay et al., 2011). In addition, sulfonated tyrosine residues on sperm-
expressed proteins, such as MFGE8, contribute to the capacity of sperm to adhere to the 
oocyte plasma membrane. For example, the tyrosylprotein sulfotransferase-2 (Tpst2) 
deficient male mouse lacks tyrosine sulfonation of MFGE8 leading to infertility (Borghei et 
al., 2006). In addition, tyrosine sulfonation of the follicle-stimulating hormone and 
luteinizing hormone receptors is required for optimal reproductive function (Costagliola et 
al., 2002; Mi et al., 2002).  
 
3.4 Role of sulfate maintenance genes in the cardiovascular system 
Nine sulfate-related genes (IDS, SULF1, GALNS, SUMF1, ARSE, ARSB, CBS, CHST14 and 
CHST3), which are expressed in blood, vascular and/or heart tissues (Fig. 3), are associated 
with cardiovascular pathologies. Six of these genes encode sulfatases which are linked to 
accumulation of glycosaminoglycans in the heart, leading to cardiac valve dysplasia or 
cardiomyopathy  (Rigante and Segni, 2002; Diez-Roux and Ballabio, 2005). In one reported 
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case, acute heart failure from valve disease was the predominant phenotype associated 
with the ARSB gene (Jurecka et al., 2011), although the clinical spectrum of sulfatase 
deficiencies usually includes neurological and/or skeletal pathologies as the major 
phenotype. Mutations in the CBS gene are also associated with cardiovascular disease 
(Dawson et al., 1996, 1997), although this has been attributed to hyperhomocysteinemia as 
a consequence of impaired homocysteine metabolism (Dudman et al., 1996) rather than 
reduced intracellular sulfate generation (Fig. 1B). Cardiovascular features of atrial septal 
defects, patent ductus arteriosus, coarctation of the aorta, and cardiac valve dysplasia are 
within the differential diagnosis of CHST14 deficient Ehlers-Danlos syndrome (Miyake et al., 
2013). CHST3 has also been linked to cardiovascular phenotypes, including mitral, tricuspid 
and/or aortic regurgitations (Tuysuz et al., 2009). The cardiac involvement of the CHST14 
and CHST3 sulfotransferase genes is proposed to be a consequence of reduced sulfate 
content of glycosaminoglycans which impairs extracellular collagen bundling and function 
(van Roij et al., 2008; Miyake et al., 2013). The endogenously generated sulfur-containing 
gases H2S and SO2 that are intermediates of the sulfate generating pathways (Fig. 1B), also 
contribute to numerous physiological and pathophysiological roles in the mammalian body 
(Medani et al., 2011; Wang et al., 2011; di Masi and Ascenzi, 2013; Wang et al., 2014; Guo et 
al., 2016; Huang et al., 2016). In particular, both H2S and SO2 modulate vascular tone and 
cardiac function, and have cardioprotective effects in animal models of systemic and 
pulmonary hypertension, atherosclerosis and cardiac ischemia-reperfusion injury (Elrod et 
al., 2007; di Masi and Ascenzi, 2013; Wang et al., 2014). These animal studies are relevant 
to the clinical situation when considering the genes involved in endogenous H2S and SO2 
generation from sulfur-containing amino acids (Fig. 1B and Table 1) are conserved across 
mammalian species. Collectively, cardiovascular phenotypes are linked to several genes in 
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this review, demonstrating the importance for maintaining sulfate homeostasis in the 
cardiovascular system. 
 
4. Role of sulfate in the metabolism of pharmacological drugs 
Sulfate is conjugated to numerous pharmacological drugs, including acetaminophen, 
tamoxifen, apomorphine, butesonide and ethinylestradiol (Kauffman, 2004). In most cases, 
sulfonation increases the water solubility and renal excretion of the drug. However, certain 
drugs such as minoxidil, which is an antihypertensive agent and hair growth stimulant, are 
activated upon sulfonation (Buhl et al., 1990; Strott, 2002). Sulfonation is a low-capacity but 
high-affinity Phase II metabolic pathway which accounts for approximately 35% of drug 
metabolism at therapeutic doses in adults, together with 50% via glucuronidation and 15% 
via oxidative pathways (McGill and Jaeschke, 2013; Lancaster et al., 2015). Overdoses of 
certain drugs can saturate the sulfonation pathway and place more pressure on the 
oxidative pathway. For example, acetaminophen overdose leads to excess levels of the 
oxidative pathway intermediate, N-Acetyl-p-Benzoquinone Imine (NAPQI), which is a 
reactive toxic product that can cause hepatotoxicity and death (Jan et al., 2014). Studies in 
mice have shown that low blood sulfate levels, due to disruption of the renal sulfate 
transporter genes Slc13a1 and Slc26a1 (Table 5), can reduce hepatic sulfonation capacity 
and enhance acetaminophen-induced hepatotoxicity (Lee et al., 2006; Dawson et al., 
2010b). This may be relevant to loss-of-function variants in the human SLC13A1 gene which 
lead to hyposulfatemia (Bowling et al., 2012), as well as the SULT1A1, SULT1A3 and 
SULT1C4 sulfotransferase genes that sulfonate acetaminophen (Yamamoto et al., 2015). 
Taken together, these studies warrant investigations into the consequences of gene 
variants, that reduce sulfonation capacity (Tables 1and 2), on drug toxicity in humans. 
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Summary 
The diverse roles of sulfate in mammalian physiology, together with the impact of sulfate-
related genes on health outcomes, cannot be underestimated. The number of genes 
associated with sulfate biology is a testament to the significance of sulfate in many tissues 
and physiological functions. Further studies are required for translating the past few 
decades of animal research into the clinic, particularly for those genes which yield 
significant pathologies in animals but have yet to be linked to human health. While interest 
in sulfate-related genes continues to expand, particularly in the fields of bone, neuroscience, 
reproduction and cardiovascular research, there is still much to be done. Expanding the list 
of clinically reportable genes opens up the possibility for genetic counselling, as well as 
developing therapeutic approaches towards treatments. In summary, this review provides 
a list of all known human genes that encode sulfate transporters, PAPS synthetases and 
transporters, enzymes involved in intracellular sulfate generation, cytosolic and 
membrane-bound sulfotransferases and sulfatases. Collectively, this review provides 
reference information for future genetic studies of sulfate biology in human health. 
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Figure legends 
Fig. 1.  Physiological roles of sulfate and pathways of sulfate homeostasis. A: Sulfate 
contributes to numerous biochemical and cellular processes in mammalian physiology. B: 
Intracellular sulfate levels are maintained by uptake of extracellular sulfate via sulfate 
transporters (T) on the plasma membrane, removal of sulfate from substrates via sulfatases 
in the cytosol and lysosome, and intermediary metabolism of methionine and cysteine via 
cystathionine β-synthase (CBS), γ-cystathionase (CTH), cysteine dioxygenase (CDO1), 
glutamic-oxaloacetic transaminase 1 (GOT1), sulfide quinone reductase (SQRDL), 
thiosulfate sulfurtransferase (TST), sulfite oxidase (SUOX) and nicotinamide-adenine 
dinucleotide phosphate (NADPH) oxidase. Sulfate is converted into PAPS via PAPS 
synthetase (PAPSS2) which is used in the cytosol by sulfotransferases (SULT) or 
transported into the Golgi via PAPS transporters (SLC35B2 and SLC35B3) and used by Golgi 
membrane-bound sulfotransferases (ST). 
 
 
Fig. 2. Distribution of 91 human genes that are involved with sulfate biology. An 
ideogram of all chromosomes with lines plotted to the corresponding location of each gene. 
Lines connect to coloured circles representing the major groups of genes involved in sulfate 
biology, as defined by the colour key. Diagrams were constructed using the online 
Phenogram tool (Wolfe et al., 2013) and chromosomal locations of genes from the online 
NCBI Gene database (http://www.ncbi.nlm.nih.gov/gene/ accessed on 25 February 2016). 
 
 
Fig. 3. Tissue distribution and pathologies linked to 28 human genes involved in 
sulfate biology. From the 28 genes linked to human pathologies (Tables 5‒7), we 
generated a heat map of approximate mRNA expression levels (as identified by the colour 
key) in 45 human tissues using data obtained from the online NCBI UniGene EST database 
http://www.ncbi.nlm.nih.gov/est/ accessed on 25 February 2016 (top). Organ systems 
with predominant pathologies for the 28 genes (bottom) were obtained by searching 
PubMed, Medline and the online NCBI OMIM database 
http://www.ncbi.nlm.nih.gov/omim/. Those pathologies reported to be associated with 
each gene were confirmed from the full text of identified publications. 
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Table 1. Genes encoding sulfate transporters, PAPS synthetases and transporters, and key 
enyzmes in the pathway of sulfate generation from amino acids.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Information was obtained from the online NCBI Gene database 
http://www.ncbi.nlm.nih.gov/gene/ accessed from 25 October 2015 to 25 February 
2016. 
  
 
Gene ID Location Aliases  
 
Sulfate transporters    
SLC4A1 109270 17q21.31 AE1, EPB3, DI, FR, SW, WD, WR, CHC, 
SAO, WD1, BND3, CD233, EMPB3, RTA1A 
SLC13A1 6561 7q31.32 NAS1, NaSi-1 
SLC13A4 26266 7q33 NAS2, SUT1, SUT-1 
SLC26A1 10861 4p16.3 EDM4, SAT-1, SAT1 
SLC26A2 1836 5q31-34 DTD, DTDST, EDM4, MST153, MSTP157, 
D5S1708 
SLC26A3 1811 7q31 CLD, DRA 
SLC26A6 65010 3p21.3  
SLC26A7 115111 8q23 SUT2 
SLC26A8 116369 6p21 TAT1, RP11-482O9.1, SPGF3 
SLC26A9 608481 1q32.1  
SLC26A11 610117 17q25.3  
PAPS synthetases 
PAPSS1 9061 4q24 ATPSK1, PAPSS, SK1 
PAPSS2 9060 10q24 ATPSK2, RP11-77F13.2, BCYM4, SK2 
PAPS transporters 
SLC35B2 610788 6p21.1 PAPST1, SLL, UGTre14 
SLC35B3 610845 6p24.3 PAPST2, CGI-19, C6orf196 
Key enzymes in the pathways of sulfur-containing amino acid catabolism 
CBS 875 21q22.3 HIP4 
CDO1 1036 5q23.2 CDO, CDO-I 
CTH 1491 1p31.1  
GOT1 2805 10q24.1-25.1 ASTQTL1, GIG18, AST1, cAspAT, cCAT 
SQRDL 58472 15q15 SQOR, CGI-44, PRO1975 
TST 7763 22q13.1 LL22NC01-146D10.3, RDS 
SUOX 6821 12q13.2  
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Table 2. Genes encoding cytosolic sulfotransferases 
 
Gene ID Location Aliases  
SULT1A1 6817 16p12.1 HAST1/2, P-PST, PST, ST1A1, ST1A3, STP, STP1, TSPST1 
SULT1A2 6799 16p12.1 HAST4, P-PST, ST1A2, STP2, TSPST2 
SULT1A3 6818 16p11.2 HAST, HAST3, M-PST, ST1A3/ST1A4, ST1A5, STM, TL-PST 
SULT1A4 445329 16 HAST3, M-PST, ST1A3/ST1A4, TL-PST 
SULT1B1 27284 4q13.3 ST1B1, ST1B2, SULT1B2 
SULT1C2 6819 2q12.3 ST1C1, ST1C2, SULT1C1, humSULTC2 
SULT1C3 442038 2q12.3 ST1C3 
SULT1C4 27233 2q12.3 SULT1C, SULT1C2 
SULT1E1 6783 4q13.1 EST, EST-1, ST1E1, STE 
SULT2A1 6822 19q13.3 DHEA-ST, DHEAS, HST, ST2, ST2A1, ST2A3, STD, hSTa 
SULT2B1 6820 19q13.3 HSST2 
SULT4A1 25830 22q13.2 BR-STL-1, BRSTL1, DJ388M5.3, NST, SULTX3, hBR-STL-1 
SULT6B1 391365 2p22.2  
Information was obtained from the online NCBI Gene database 
http://www.ncbi.nlm.nih.gov/gene/ accessed from 25 October 2015 to 25 February 
2016. 
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Information was obtained from the online NCBI Gene database 
http://www.ncbi.nlm.nih.gov/gene/ accessed from 25 October 2015 to 25 February 2016. 
 
 
 
Table 3 . Genes encoding membrane bound sulfotransferases  
 
Gene ID Location Aliases  
CHST1 8534 11p11.2 C6ST, KSST, GST-1, KS6ST, KSGal6ST 
CHST2 9435 3q24 C6ST, GST-2, GST2, Gn6ST-1, glcNAc6ST-1 
CHST3 9469 10q22.1 C6ST, C6ST1, HSD 
CHST4 10164 16q22.2 GST3, GlcNAc6ST2, HECGLCNAC6ST, LSST 
CHST5 23563 16q22.3 I-GlcNac-6-ST, I-GlcNAc6ST, glcNAc6ST-3, gn6st-3, hlGn6ST 
CHST6 4166 16q22 MCDC1 
CHST7 56548 Xp11.23 RP1-71L16.8, C6ST-2 
CHST8 64377 19q13.1 GALNAC4ST1, GalNAc4ST 
CHST9 83539 18q11.2 UNQ2549/PRO6175, GALNAC4ST-2 
CHST10 9486 2q11.2 HNK-1ST, HNK1ST 
CHST11 50515 12q C4ST, C4ST-1, C4ST1, HSA269537 
CHST12 55501 7p22 UNQ500/PRO1017, C4S-2, C4ST-2, C4ST2 
CHST13 166012 3q21.3 C4ST3 
CHST14 113189 15q15.1 UNQ1925/PRO4400, ATCS, D4ST1, HNK1ST 
CHST15 51363 10q26 BRAG, GALNAC4S-6ST, RP11-47G11.1 
GAL3ST1 9514 22q12.2 CST 
GAL3ST2 64090 2q37.3 hCG_31746, GAL3ST-2, GP3ST 
GAL3ST3 89792 11q13.1 GAL3ST-3, GAL3ST2 
GAL3ST4 79690 7q22.1 PP6968, GAL3ST-4 
HS2ST1 9653 1p22.3 dj604K5.2 
HS3ST1 9957 4p16 3OST, 3OST1 
HS3ST2 9956 16p12 3OST2, 30ST2 
HS3ST3A1 9955 17p12 UNQ2551/PRO6180, 30ST3A1, 3OST3A1 
HS3ST3B1 9953 17p12 30ST3B1, 30ST3B1 
HS3ST4 9951 16p11.2 30ST4, 30ST4, 3-OST-4, h3-OST-4 
HS3ST5 222537 6q21 3-OST-5, 3OST5, HS3OST5, NBLA04021 
HS3ST6 64711 16p13.3 HS3ST5 
HS6ST1 9394 2q21 HH15, HS6ST 
HS6ST2 90161 Xq26.2 RP3-435D1.3 
HS6ST3 266722 13q32.1 HS6ST-3 
NDST1 3340 5q33.1 HSST, NST1 
NDST2 8509 10q22 NST2, HSST2 
NDST3 9348 4q26 HSST3 
NDST4 64579 4q26 NDST-4, NHSST4 
TPST1 8460 7q11.21 TANGO13A 
TPST2 8459 22q12.1 CTA-445C9.10-003, TANGO13B 
UST 10090 6q25.1 2OST 
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Information was obtained from the online NCBI Gene database 
http://www.ncbi.nlm.nih.gov/gene/ accessed from 25 October 2015 to 25 
February 2016. 
 
  
Table 4 .  Genes encoding sulfatases and sulfatase modifying factors  
 
Gene ID Location Aliases  
Sulfatases    
ARSA 410 22q13.33 MLD 
ARSB 411 5q14.1 ASB, G4S, MPS6 
STS 412 Xp22.32 ARSC, ARSC1, ASC, ES, SSDD, XL1 
ARSD 414 Xp22.3 ASD 
ARSE 415 Xp22.3 ASE, CDPX, CDPX1, CDPXR 
ARSF 416 Xp22.3 ASF 
ARSG 22901 17q24.2 ASG, UNQ839/PRO1777, KIAA1001 
ARSH 347527 Xp22.33 ASH, sulfatase, arylsulfatase H 
ARSI 340075 5q32 Arylsulfatase I 
ARSJ 79642 4q26 Arylsulfatase J 
ARSK 153642 5q15 TSULF 
GALNS 2588 16q24.3 GALNAC6S, GAS, MPS4A, GALN6S 
GNS 2799 12q14 G6S 
IDS 3423 Xq28 MPS2, SIDS 
SGSH 6448 17q25.3 HSS, MPS3A, SFMD 
SULF1 23213 8q13.1 HSULF-1, SULF-1 
SULF2 55959 20q12-13.2 HSULF-2, RP5-1049G16.1 
Sulfatase Modifying Factors 
SUMF1 285362 3p26.1 UNQ3037, AAPA3037, FGE 
SUMF2 607940 7q11.1 PSEC0171, pFGE 
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Table 5. Pathophysiology linked to sulfate transporters, PAPS synthetases and transporters, and 
the enzymes involved in sulfate generation from amino acids 
Information was obtained from PubMed, Medline and the online NCBI OMIM http://www.ncbi.nlm.nih.gov/omim/ 
and OMIA http://omia.angis.org.au/home/ databases accessed from 25 October 2015 to 25 February 2016. 
Gene Species Condition Reference 
SLC4A1 
 
 
 
 
 
 
SLC13A1 
Human 
 
 
Cow 
 
Mouse 
Zebrafish 
Human 
Hereditary spherocytosis/stomatocytosis, Southeast 
Asian ovalocytosis, distal renal acidosis, developmental 
delay 
Hereditary spherocytosis, growth retardation, mild 
acidosis 
Spherocytosis and hemolysis 
Dyserythropoiesis 
Hyposulfataemia, renal sulfate wasting 
Bruce et al., 1997; Bruce et 
al., 2005 
 
Inaba et al., 1996 
 
Peters et al., 1996 
Paw et al., 2003 
Bowling et al., 2012 
 Mouse Hyposulfataemia, growth retardation, late gestational 
fetal loss, seizures, behavioural abnormalities 
Dawson et al., 2003, 2004, 2005, 2011 
 Sheep Hyposulfataemia, osteochondrodysplasia, growth 
retardation  
Zhao et al., 2012 
 Dog Hyposulfataemia, osteochondrodysplasia, growth 
retardation  
Neff et al., 2012 
Slc13a4  Mouse Fetal abnormalities, including skeletal defects, vascular 
haemorrhaging, craniofacial malformations and 
embryonic death 
Rakoczy et al., 2015b 
Slc26a1 Mouse Hyposulfataemia, hyperoxaluria, renal stones Dawson et al., 2010b 
SLC26A2 Human Skeletal dysplasias Dawson and Markovich, 2005 
 Mouse Growth retardation, skeletal dysplasia, joint contractures, 
delay in formation of secondary ossification centre and 
osteoporosis of long bones 
Forlino et al., 2005 
SLC26A3 Human Congenital chloride diarrhoea  Hoglund et al., 2001 
 Mouse Fatal infectious diarrhoea Borenshtein et al., 2009 
SLC26A6 Human Increased kidney stone risk Lu et al., 2016 
 Mouse Hyperoxaluria, elevated plasma oxalate, defective oxalate 
secretion (Bird’s disease – kidney stones) 
Jiang et al., 2006 
Slc26a7 Mouse Distal renal tubular acidosis, impaired gastric acid 
secretion 
Xu et al., 2009 
SLC26A8 Human Spermatogenic failure Dirami et al., 2013 
 Mouse Reduced sperm motility, capacitation defect  Rode et al., 2012b 
SLC26A9 Human Diffuse idiopathic bronchiestasis Bakouh et al., 2013 
 Mouse Gastric hypochlorhydria, airway mucus obstruction in 
inflammatory condition, elevated systemic arterial 
pressure 
Xu et al., 2008; Amlal et al., 2013 
Slc35b2 Drosophila Pupal lethality  Kamiyama et al., 2003 
 Zebrafish Cartilage defects Clément et al., 2008 
PAPSS2 Human Brachyolmia type 4 with mild epiphyseal and 
metaphyseal changes, premature pubarche, androgen 
excess 
Faiyaz ul Haque et al., 1998; Noordam et al., 
2009; Oostdijk et al., 2015 
 Mouse Brachymorphic, shortened limbs, dome shaped skull, 
short thick tail, 25% reduction in axial skeleton 
Faiyaz ul Haque et al., 1998 
CBS Human Hyperhomocysteinemia, neurological deficits, dislocation 
of the optic lens, increased bone fracture risk, premature 
arteriosclerosis and thromboembolism  
Dawson et al., 1996, 1997 
 Mouse Mod-severe homocysteinemia, post-natal death within 1 
month of age, abnormal lipid metabolism 
Watanabe et al., 1995 
Cdo1 
 
CTH 
Mouse 
 
Human 
High postnatal mortality, growth retardation, male 
infertility, kyphosis, irregular shaped cranium 
Cystathioninuria, neurological deficits 
Ueki et al., 2011 
 
Wang and Hegele, 2003 
 Mouse Hydrogen sulfide reduction, hypertension, diminished 
endothelium-dependent vasorelaxation 
Yang et al., 2008; Ishii et al., 2010 
SUOX 
 
Human 
Cow 
Sulfite oxidase deficiency, neurological impairment 
Arachnomelia 
Kisker et al., 1997 
Drögemüller et al., 2010 
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Table 6. Pathophysiology linked to sulfotransferase genes 
 
Information was obtained from PubMed, Medline and the online NCBI OMIM 
http://www.ncbi.nlm.nih.gov/omim/ and OMIA http://omia.angis.org.au/home/ databases accessed 
from 25 October 2015 to 25 February 2016. 
 
  
Gene Species Condition Reference 
Sult1e1 Mouse Placental thrombosis and spontaneous fetal loss. Tong et al., 2005 
Chst2 Mouse Peripheral lymph node addressin (PNAd) elimination and 
reduced lymphocyte homing 
Uchimura et al., 2002 
CHST3 Human Joint dislocations, vertebral changes,  heart valve 
abnormalities, brachydactyly,  spondyloepiphyseal 
dysplasia, bilateral mixed hearing loss 
Thiele et al., 2004; Tuysuz et 
al., 2009;  Unger et al., 2010; 
Waryah et al., 2016 
Chst5 Mouse Thin corneas Hayashida et al., 2006 
CHST6 Human Macular corneal dystrophy Akama et al., 2000; El-Ashry 
et al., 2002 
 Dog Macular corneal dystrophy Tetas Pont et al., 2015 
CHST8 Human Peeling skin syndrome Cabral et al., 2012 
 Mouse Increased luteinizing hormone, testosterone, estrogen  Mi et al., 2008b 
CHST11 Human Skeletal malformation, malignant lymphoproliferative 
disease 
Chopra et al., 2015 
 Mouse Chondrodysplasia Klüppel et al., 2005 
CHST14 Human Ehlers-Danlos syndrome Malfait et al., 2010; Miyake 
et al., 2010 
GAL3ST4 Human Pectus excavatum Wu et al., 2012 
Hs2st Mouse Eye and skeletal defects, kidney agenesis, neonatal death Bullock et al., 1998 
Hs3t1 Mouse Reduced fecundity delayed placental development de Agostini, 2006 
Hs3st1  Mouse Reductions in anticoagulant heparan sulphate, genetic 
background-specific lethality, intrauterine growth 
retardation 
HajMohammadi et al., 2003 
HS6ST1 Human Hypogonadotrophic hypogonadism with and without 
anosmia 
Tornberg et al., 2011 
 Mouse Reduced fecundity, perturbed placental development  Habuchi et al., 2007 
NDST1 Human Intellectual disability, epilepsy, muscular hypotonia Reuter et al., 2014 
 Mouse Respiratory distress and atalectasis and neonatal death Fan et al., 2000 
 Drosophila Impaired long-term memory Reuter et al., 2014 
Ndst2  Mouse Altered mast cell morphology, reduced histamine, inability 
to synthesise sulfated heparin 
Forsberg et al., 1999; 
Humphries et al., 1999 
Tpst1 Mouse Fetal loss and reduced body weight Ouyang et al., 2002 
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Table 7. Pathophysiology linked to sulfatase and sulfatase modifying factor genes 
 
Information was obtained from PubMed, Medline and the online NCBI OMIM 
http://www.ncbi.nlm.nih.gov/omim/ and OMIA http://omia.angis.org.au/home/ databases accessed 
from 25 October 2015 to 25 February 2016. 
 
 
Gene Species Condition Reference 
ARSA Human Metachromatic leukodystrophy Diez-Roux and Ballabio, 
2005; Sardiello et al., 2005 
ARSB Human Maroteux-Lamy syndrome Diez-Roux and Ballabio, 
2005; Sardiello et al., 2005 
 Mouse Facial dysmorphia, dystosis multiplex, GAG build up in 
connective tissue, reticuloendothelial cells and cartilage 
Evers et al., 1996 
 Rat Facial dysmorphia, dysostosis multiplex, increased urinary 
excretion of glucosaminoglycans 
Yoshida et al., 1994 
 Cat Dwarfism, facial dysmorphia, dermatan sulfaturia, 
lysosomal inclusions in most tissues, corneal clouding, 
degenerative joint disease, abnormal leukocyte inclusions. 
Crawley et al., 1998 
 
 
 
 
ARSE 
Dog 
 
 
 
Human 
Epiphyseal dysplasia, malformed vertebral bodies, 
luxation / subluxation of appendicular and lumbosacral 
joints with hypoplasia of the odontoid process and hyoid 
apparatus. 
Chondrodysplasia punctata 1 (X-linked recessive) 
Jolly et al., 2012 
 
 
 
Franco et al., 1995 
Arsg Dog Cerebellar ataxia, neuronal ceroid lipofuscinoses Abitbol et al., 2010 
 Mouse Mucopolysaccharidosis, behavioural deficits Kowalewski et al., 2012 
STS Human X-linked ichthyosis Ballabio et al., 1987 
GALNS Human Morquio A syndrome – metabolic syndrome  Diez-Roux and Ballabio, 
2005 
 Mouse Accumulated glycosaminoglycans in tissues – skeletal, 
neurological, ocular, skin and connective tissue problems 
Tomatsu et al., 1993 
GNS Human 
 
Goat 
Sanfilippo D syndrome 
 
Neurological manifestations 
Diez-Roux and Ballabio, 
2005 
Thompson et al., 1992; 
Cavanagh et al., 1995 
IDS Human Hunter syndrome Diez-Roux and Ballabio, 
2005 
SGSH Human 
 
Dog 
Sanfilippo A syndrome 
 
Progressive neurologic disease,  pelvic limb ataxia  and  
spinocerebellar ataxia 
Diez-Roux and Ballabio, 
2005 
Fischer et al., 1998 
SULF1 Human Mesomelia-synostoses syndrome Isidor et al., 2010 
 Mouse Developmental defects, neonatal lethality Holst et al., 2007 
Sulf2 Mouse Developmental defects, neonatal lethality Holst et al., 2007 
SUMF1 Human Multiple sulfatase deficiency Dierks et al., 2003 
 Mouse Skeletal abnormalities, congenital growth retardation Settembre et al., 2007 
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